NYSE MKT LLC · AZTR
+4.81% · +$0.0061 · Vol 2.0M
Market closed · last close 4:00 PM ET · price as of 20:00:00 ET
Azitra Inc

Azitra Inc

Biotechnology
$0.1328
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
AZTR
Azitra Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

36/ 100
Veridion Score
SELL BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AZTR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AZTR catalysts
About Azitra Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
13
Country
US

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.1350
Day high
$0.1405
Day low
$0.1300
Previous close
$0.1267
52W high
$1.07
-87.59% from high
52W low
$0.1250
1% of range
Market cap
$8M
EPS
$-1.2700
Beta
-0.78
Shares out
60.6M
Volume
2M
1.30× rel vol
Avg volume
1.5M
VWAP
$0.1352
Price history computed in-house
1W
-1.85%
1M
+5.15%
3M
-36.76%
1Y
-85.62%
YTD
-49.85%
SMA 50 $0.1516 · below
SMA 200 $0.2313 · below
52W position 1%

AZTR overview

Veridion Score
36
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AZTR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AZTR Form 4 filings
Public disclosures

Congress activity in AZTR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AZTR in the cached public ledger.

Federal contracts

AZTR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AZTR in this window.
Lobbying spend

AZTR lobbying filings, year to date.

Registered lobbying filings matched to Azitra Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AZTR in this window.
Loading news for AZTR
Analyst ratings
Sovereign unlock shows live analyst consensus for AZTR.
Options
Sovereign unlock shows live options positioning for AZTR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.